

Please delete the sequence listing from the specification, page 57, line 26 to page 75, line 9 and insert the new sequence listing (attached hereto) as a separately paginated document which is part of the present application.

In the Claims:

Please delete claims 1-3 and add new claims 4-18 as follows:

A1
00465703-1022000
0022000-0022000

--4. An isolated DNA molecule capable of transcription to a messenger RNA which is modified from a form encoding a nucleocapsid protein of an L serogroup *Tospovirus* so that it does not translate to the nucleocapsid protein, wherein, when the DNA molecule is transformed into a plant cell, it is capable of being transcribed into messenger RNA which exists at low level density readings of 15-50 as measured using a Hewlett ScanJet and Image Analysis Program.--

--5. A DNA molecule according to claim 4, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--6. A recombinant DNA expression system comprising an expression vector into which is inserted a heterologous DNA molecule according to claim 4.--

--7. A plant cell transformed with a heterologous DNA molecule according to claim 4.--

--8. A transgenic plant containing the DNA molecule according to claim 4.--

--9. A method of treating a plant cell comprising:
transforming a plant cell with a DNA molecule according to claim 4
and

transcribing the DNA molecule under conditions effective to maintain the messenger RNA in the plant cell at low level density readings of 15-50, as measured

using the Hewlett ScanJet and Image Analysis Program, wherein the plant cell acquires resistance to an L serogroup *Tospovirus*.--

--10. A method of imparting to a plant cell resistance to infection by an I serogroup *Tospovirus*, said method comprising:

transforming a plant cell with a DNA molecule encoding a nucleocapsid protein of an L serogroup *Tospovirus*, wherein the DNA molecule is expressed to produce an ELISA level of OD_{405nm} = 0.50 to 1.00 of the nucleocapsid protein in the plant cell, as measured using an antibody raised against the nucleocapsid protein of *Tospovirus* isolate TSWV-BL, and the plant cell acquires resistance to an I serogroup *Tospovirus*.--

--11. A method according to claim 10, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--12. A method according to claim 10, wherein the I serogroup *Tospovirus* is selected from the group consisting of INSV-Beg and INSV-LI.--

--13. A method of imparting to a plant cell resistance to infection by L serogroup *Tospoviruses*, said method comprising:

transforming a plant cell with a DNA molecule encoding a nucleocapsid protein of an L serogroup *Tospovirus*, wherein the DNA molecule is expressed to produce an ELISA level of OD_{405nm} = 0.02 to 0.20 of the nucleocapsid protein in the plant cell, as measured using an antibody raised against the nucleocapsid protein of *Tospovirus* isolate TSWV-BL, and the plant cell acquires resistance to the L serogroup *Tospovirus* and a second L serogroup *Tospovirus*.--

--14. A method according to claim 13, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--15. A method of imparting to a plant cell resistance to infection to a *Tospovirus* comprising:


transforming a plant cell with a DNA molecule encoding a nucleocapsid protein or polypeptide of a serogroup L *Tospovirus* under conditions effective to render the plant cell resistant to infection by serogroup L *Tospovirus* isolates and a serogroup 2 *Tospovirus* isolate.--

A7
cont
--16. A method according to claim 15, wherein the serogroup 2 *Tospovirus* isolate is a TSWV-B *Tospovirus* isolate.--

--17. A transgenic plant containing a heterologous DNA molecule encoding a nucleocapsid protein or polypeptide of a serogroup L *Tospovirus*, wherein the transgenic plant, upon challenge with both a *Tospovirus* isolate belonging to serogroup L and a *Tospovirus* isolate belonging to serogroup 2, exhibits resistance to both the L serogroup *Tospovirus* isolate and the serogroup 2 *Tospovirus* isolate.--

--18. A transgenic plant according to claim 17, wherein the serogroup 2 *Tospovirus* isolate is a TSWV-B *Tospovirus* isolate.--

Date: October 22, 1999


Edwin V. Merkel
Registration No. 40,087
Attorney for Applicants

Nixon Peabody LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1128
Facsimile: (716) 263-1600